Analytical and Chemical Enhancements to Improve Efficacy and Accuracy of Therapeutic Oligonucleotides
See how top pharma players are addressing impure, unstable, and off-target oligos
Boosting the Efficacy of Safe, Scalable, & Precise Vaccines
Innovations in mRNA Technology, RNA Therapeutics, and Cancer Immunotherapy for 2024
.png)
Tumbler: A Highly Customizable Antibody Optimization Suite
On-demand presentation, presented by Michali Izhaky, Bioinformatics Scientist at Charles River
Leading Innovations in Fab, ScFv, & VHH Production and Engineering
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Advancing Immunotherapy: The Critical Role of GMP-Grade Cytokines in Cell Therapy
On-demand webinar presented by Ritwika Biswas, Field Application Scientist at Sino Biological
Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Unlocking the Future of Immune Cancer Therapy
A concise report featuring insights from the prominent though leaders of Immuno 2024.
Stem Cell Therapy
Beating the System with Advanced High Throughput and Real-Time Analytics for Biopharmaceutical Manufacturing
Can advanced analytical processing and real-time data monitoring conquer the complexity of Bio-pharmaceutical manufacturing? We ask Udayanath Aich, Director at Bristol Myers Squibb.
Drug Discovery & Development
Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune Escape
Synthetic immunity mediated by bispecific T Cell engagers may help to bypass immune escape posed by a lack of appropriate immunotherapeutic target expression. Bispecific T Cell engagers offer a solution to the issue of immune escape in cancer treatments, with the potential to become off-the-shelf therapeutics.
Manufacturing & Bioprocessing
Process Development and Manufacturing Avenues for Gene Therapy Vectors
Hemant Dhamne, Head of Process Development of Gene Therapy at King's College London, discusses the process of viral vector production, the current and future manufacturing technologies, and challenges in the field.
